Related Content
May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...
May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...
July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of ...
January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...
October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's ...
September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy ...
September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga ...
March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of ...
November 15, 2018 — AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes ...
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and co ...